Virtual Library
Start Your Search
M. Phillips
Author of
-
+
P1.03 - Poster Session with Presenters Present (ID 455)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Radiology/Staging/Screening
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.03-045 - Screening for Lung Cancer with Early CDT-Lung Blood Biomarkers and Computed Tomography (ID 6148)
14:30 - 14:30 | Author(s): M. Phillips
- Abstract
Background:
The Early Cancer Detection Test (CDT)-Lung is a serum-based biomarker consisting of a panel of tumor-associated autoantibodies that has been shown to detect lung cancer. We hypothesized that this biomarker when used in combination with a low-dose CT (LDCT) in screening of an at-risk population would increase the detection of early stage lung cancer.
Methods:
A prospective study of 1,600 subjects at high risk for lung cancer was designed. Eligibility criteria included persons 50-75 years of age, current or former smokers of ≥ 20 pack years and ˂ 10 years since quit smoking. Those with a history of lung cancer in first-degree relative(s) and any history of smoking were included. Exclusion criteria were any history of cancer within 10 years (except skin cancer), any use of oxygen, and life expectancy of < 5 years. Those fitting inclusion criteria received the Early CDT-Lung blood test and a LDCT. A nodule of ≥ 3mm was considered as a positive scan. The Early CDT-Lung test was considered positive if any one of the seven autoantibodies was positive. Telephonic follow-up was conducted over two years.
Results:
From May 2012 through June 2016, 1235 individuals were enrolled. The cohort median age was 59 years with 55% female and 45% male gender distribution. Fifty-two per cent were current smokers while 48% were former smokers. Seventy-one per cent of the LDCTs were negative for any lung nodule while 29% were positive. The Early CDT-Lung biomarker was positive in 88 (7%) of participants. In those with a positive LDCT (n=352), the biomarker was positive in 30 (8.5%). As of June 30, 2015, there have been seven confirmed lung cancers: two limited stage small cell, two Stage IB adenocarcinoma (ACA), and three Stage IA (two ACA and one squamous cell). The Early CDT-Lung blood test was positive in 2 of the 7 (29%) total cancers, both stage 1A. Early CDT-Lung was positive in 2 of 5 (40%) Stage IA/B lung cancers in total. Early CDT-Lung was negative in the two small cell cancers. There are 58 Early CDT-Lung biomarker positive individuals with a LDCT without nodules. (NCT01700257)
Conclusion:
The Early CDT-Lung biomarker was more likely to be positive in patients with nodules and lung cancer cases, particularly early stage lung cancer. Accrual to the study and follow-up of 58 biomarker positive but LDCT negative participants continues.
